Related Experiment Videos
Preparation of [186Re]Re-DMSA and its bio-distribution studies
K Kothari1, M R Pillai, P R Unni
1Isotope Division, Bhabha Atomic Research Centre, Mumbai, India.
Summary
Rhenium-186(V)-DMSA (186Re(V)-DMSA) shows promise for treating medullary carcinoma, similar to technetium-99m(V)-DMSA. Studies in rats indicate stable properties and potential for clinical trials, with kidney uptake manageable by pH adjustment.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
Background:
- Technetium-99m(V)-DMSA is a standard for medullary carcinoma imaging.
- Rhenium-186(V)-DMSA is proposed as a therapeutic alternative.
Purpose of the Study:
- To synthesize and evaluate 186Re(V)-DMSA for potential medullary carcinoma therapy.
- To assess the biodistribution and stability of 186Re(V)-DMSA in vivo.
Main Methods:
- Synthesis of 186Re(V)-DMSA using stannous chloride reduction.
- Biodistribution studies in Wistar rats.
- In vitro stability assays.
Main Results:
- 186Re(V)-DMSA preparation was successful.
- Pharmacological behavior mirrors 99mTc(V)-DMSA, with slightly higher kidney uptake.
- Kidney uptake was significantly reduced by adjusting the complex's pH to 8.
- In vitro studies confirmed the complex's stability.
Conclusions:
- 186Re(V)-DMSA is a stable radiopharmaceutical with potential for medullary carcinoma treatment.
- Biodistribution is favorable, and kidney uptake can be modulated.
- Further clinical trials are warranted.